Logo

Editas Medicine: Bruce Eaton, Gad Berdugo

Jul 26, 2021

Bruce Eaton has been promoted to executive VP and chief business officer of genome editing company Editas Medicine. He is replacing Gad Berdugo as chief business officer, who has stepped down and is leaving the company. Eaton has worked with Editas since 2015, first as a consultant and later as a research collaborator, before joining the firm in 2018 as senior VP of chemistry and site head for Boulder after the firm acquired assets from i2 Pharmaceuticals, where Eaton was founder and CEO. Before that, he was chief operating officer of SomaLogic, and prior to that, VP of NexaGen. He holds a PhD in chemistry from the University of California, Berkeley, and BS degrees in chemistry and biology from the University of Oregon.

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.